| |
| |
|
| Insider
Information: |
Goddard Glenn |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
69,213 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,611,279 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
69,213 |
|
|
| Total
Value |
$1,611,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -74.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agios Pharmaceuticals Inc |
AGIO |
Senior Vice President,... |
2015-09-24 |
0 |
2014-01-21 |
0 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
69,213 |
2021-08-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
61 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-07-17 |
4 |
OE |
$0.69 |
$76,603 |
D/D |
13,000 |
13,000 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,720 |
14,769 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-02-09 |
4 |
OE |
$0.69 |
$331,237 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2014-09-26 |
4 |
OE |
$0.69 |
$91,222 |
D/D |
17,500 |
17,500 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
17,831 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-05 |
4 |
OE |
$19.27 |
$385,400 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-31 |
4 |
OE |
$14.58 |
$469,374 |
D/D |
24,800 |
24,800 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$158,053 |
D/D |
(5,365) |
40,585 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,484 |
42,888 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
45,950 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,628 |
69,213 |
0 |
- |
|
61 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
